Alterity Therapeutics Limited
Research Alterity Therapeutics Limited (PBN) on Bullrun: market cap EUR 69.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPBN
- ExchangeF
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 69.60M
- Financial periodFY2025
- RevenueAUD 0
- Net income-AUD 12.15M
- Free cash flow-AUD 11.45M
Valuation Snapshot
latest market cap is EUR 69.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | AUD 0 | -AUD 12.15M | -AUD 11.45M | n/a | n/a | AUD 33.16M | AUD 155.46K | AUD 42.40M |
| FY2024 | AUD 0 | -AUD 19.12M | -AUD 12.61M | n/a | -0.01 | AUD 12.64M | AUD 159.05K | AUD 13.80M |
| FY2023 | AUD 0 | -AUD 13.81M | -AUD 20.04M | n/a | 0 | AUD 15.77M | AUD 210.38K | AUD 22.81M |
| FY2022 | AUD 0 | -AUD 12.85M | -AUD 12.43M | n/a | -0.01 | AUD 34.81M | AUD 117.49K | AUD 35.47M |
| FY2021 | n/a | n/a | n/a | n/a | -0.01 | n/a | n/a | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 69.60M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Alterity Therapeutics Limited
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Alterity Therapeutics Limited's market cap?
Alterity Therapeutics Limited's market capitalization is EUR 69.60M.
What does Alterity Therapeutics Limited do?
Alterity Therapeutics Limited is engages in research and development of Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase II clinical trial for the treatment of Parkinson's disease.